Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1991 1
1996 2
1999 2
2000 1
2001 5
2002 4
2003 1
2004 2
2005 7
2006 6
2007 8
2008 9
2009 6
2010 4
2011 5
2013 2
2014 1
2015 1
2016 3
2017 4
2018 3
2019 3
2020 2
2021 3
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 20044233

78 results

Results by year

Filters applied: . Clear all
Page 1
Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma.
Machover D, Delmas-Marsalet B, Misra SC, Ulusakarya A, Gumus Y, Frénoy N, Guettier C, Saffroy R, Innominato P, Almohamad W, Brahimi N, Haydar M, Goldschmidt E. Machover D, et al. Biomed Pharmacother. 2010 Feb;64(2):83-7. doi: 10.1016/j.biopha.2009.11.001. Epub 2009 Dec 9. Biomed Pharmacother. 2010. PMID: 20044233 Clinical Trial.
Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma.
Machover D, Delmas-Marsalet B, Misra SC, Gumus Y, Goldschmidt E, Schilf A, Frénoy N, Emile JF, Debuire B, Guettier C, Farrokhi P, Boulefdaoui B, Norol F, Parquet N, Ulusakarya A, Jasmin C. Machover D, et al. Ann Oncol. 2001 Oct;12(10):1439-43. doi: 10.1023/a:1012501305214. Ann Oncol. 2001. PMID: 11762817 Free article. Clinical Trial.
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschütz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG. Mey UJ, et al. Cancer Invest. 2006 Oct;24(6):593-600. doi: 10.1080/07357900600814490. Cancer Invest. 2006. PMID: 16982464 Clinical Trial.
Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y, Oshiro A, Tsujimura A, Yamamoto K, Morishima Y. Oki Y, et al. Cancer Sci. 2008 Jan;99(1):179-84. doi: 10.1111/j.1349-7006.2007.00662.x. Epub 2007 Nov 7. Cancer Sci. 2008. PMID: 17991293 Free article. Clinical Trial.
78 results